Trial Profile
Phase 2 Proof of Concept Study of a Candidate Aminoquinoline Antimalarial (AQ-13)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2017
Price :
$35
*
At a glance
- Drugs AQ 13 (Primary)
- Indications Malaria
- Focus Proof of concept; Therapeutic Use
- 29 Dec 2017 New trial record
- 01 Dec 2017 Results published in The Lancet Infectious Diseases